Quantifying Medicare prescription payment plan benefits under Medicare Part D

The Medicare prescription payment plan (MPPP) enables beneficiaries to convert prescription out-of-pocket (OOP) costs into a capped monthly bill. Clinicians and patients lack practical, mechanism-based guidance on when MPPP meaningfully smooths costs versus when it provides limited or counterproductive value. Quantifying conditions under which MPPP improves monthly affordability and predictability, to derive simple, portable rules for clinical counseling, has not been systematically evaluated.

Using diabetes regimens as a clinically familiar price-tier model, quantify how MPPP changes monthly payments across plan designs, medication regimens, fill cadences, and enrollment dates, as well as identify mechanism-based patterns that may inform patient-specific counseling.

Medication regimens comprised a generic diabetes backbone and brand-name add-ons using Jardiance (a mid-priced proxy) and Ozempic (a high-priced proxy), administered alone or in combination, to simulate monthly OOP costs with and without enrolling in MPPP, under four canonical Part D plan designs. We modeled 30- vs. 90-day fills and MPPP enrollment in January, July, or October. Monthly payment trajectories were the foundational outcomes; six study-developed descriptive measures summarized first-bill relief, peak-payment reduction, variability, and late-year payment concentration.

In a deductible/co-insurance plan with brand therapy, MPPP produced payment-smoothing benefits (PBR% ≈ 40-75%, FBR% ≈ 40-80%, VR% ≈ 40-60%, DSI ≈1.0-1.4), largest for Ozempic-like or two-brand regimens and with 90-day fills. July starts retained these gains, and October starts still yielded meaningful improvements under a 90-day supply. In flat-copayment plans, generic-only or single mid-priced brand regimens showed PBR ≈ 0 and VR% ≤0 with higher late-year concentration (YES% ≥ 45, DSI ≥ 2), with exceptions for high-cost two-brand regimens on 90-day fills.

MPPP is most effective when paired with deductibles or co-insurance plans for mid- to high-priced brand-name medications; even mid- and late-year starts can be advantageous. In flat-copayment plans or generic-only regimens, benefits are minimal, and late-year concentration can worsen. Lower early payments may be followed by MPPP bills that exceed the corresponding standard Part D payments later in the year. These mechanism-anchored rules generalize beyond diabetes to other conditions with similar price tiers under Part D.